Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
New Horizon Health, a pioneer in the colorectal cancer screening market in China, is looking to raise up to USD 300m to list via a Hong Kong listing. NH Health provides cancer screen kits for convenient early screening targeting populations recommended for regular cancer screening. The company's approved product ColoClear has an impressive accuracy compared with peer products for colorectal cancer. In addition to the ColoClear, it also offered a more mass-market product, Pupu Tube for home-...
Antengene is a China-based biotech company with a focus on in-licensed innovative oncology drugs. The company was founded by Dr Jay Mei, an ex-Celgene scientist with proven experience in drug development. The company has started book building to raise up to USD 359m to list in Hong Kong. In our previous note, we discussed that its ATG-010 has a small proven indication for r/r MM and r/r DLBCL (both are lymphoma), though it has the potential of indication expansion. We believe the indication and...
Antengene is a China-based biotech company with a focus on in-licensed innovative oncology drugs. The company was founded by Dr Jay Mei, an ex-Celgene scientist with proven experience in drug development. It is planning to raise up to USD 200m. In our previous note, we discuss that its ATG-010 has a small proven indication for r/r MM and r/r DLBCL (both are lymphoma), though it has the potential of indication expansion. We believe the Indication and demand for ATG-008 is bigger than ATG-010 as ...
JW Therapeutics is a leading China-based cell therapy company with the most advanced progress for the CAR-T commercialization. The company has started book building to raise up to USD 300m to list in Hong Kong. In our previous note, we discussed that the company is backed by a strong shareholder Juno, and has a strong foundation in the technology underlying the CAR-T therapy, which is demonstrated by its superior safety data for its Relma-cel. In addition to the CD19 target, the company has als...
Antengene, a China-based biotech company with a focus on in-licensed innovative oncology drugs. The company was founded by Dr Jay Mei, an ex-Celgene scientist with proven experience in drug development. It is planning to raise up to USD 200m. We are of the view that its ATG-010 has a small proven indication for r/r MM and r/r DLBCL (both are lymphoma), though it has the potential of indication expansion. We believe the Indication and demand for ATG-008 is bigger than ATG-010 as it is targetin...
JW Therapeutics is a leading China-based cell therapy company with the most advanced progress for the CAR-T commercialization. The company aims to raise up to USD 300m. In our previous note, we discussed that the company is backed by a strong shareholder Juno, and has a strong foundation in the technology underlying the CAR-T therapy, which is demonstrated by its superior safety data for its Relma-cel. In addition to the CD19 target, the company has also obtained the technology for the BCMA tar...
JW Therapeutics is a leading China-based cell therapy company with the most advanced progress for the CAR-T commercialization. The company aims to raise up to USD 300m. Backed by a strong shareholder Juno, the company has a strong foundation in the technology underlying the CAR-T therapy, which is demonstrated by its superior safety data for its Relma-cel. In addition to the CD19 target, the company has also obtained the technology for BCMA target. In addition, the company has T-cell receptor...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.